S&P 500   3,959.73 (-0.10%)
DOW   33,686.54 (-0.28%)
QQQ   284.11 (+0.09%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.81 (-2.51%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.21 (-1.70%)
DIS   93.94 (+1.50%)
AMC   5.85 (-3.62%)
PYPL   74.04 (-0.24%)
PFE   51.94 (+0.31%)
NFLX   324.46 (+4.58%)
S&P 500   3,959.73 (-0.10%)
DOW   33,686.54 (-0.28%)
QQQ   284.11 (+0.09%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.81 (-2.51%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.21 (-1.70%)
DIS   93.94 (+1.50%)
AMC   5.85 (-3.62%)
PYPL   74.04 (-0.24%)
PFE   51.94 (+0.31%)
NFLX   324.46 (+4.58%)
S&P 500   3,959.73 (-0.10%)
DOW   33,686.54 (-0.28%)
QQQ   284.11 (+0.09%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.81 (-2.51%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.21 (-1.70%)
DIS   93.94 (+1.50%)
AMC   5.85 (-3.62%)
PYPL   74.04 (-0.24%)
PFE   51.94 (+0.31%)
NFLX   324.46 (+4.58%)
S&P 500   3,959.73 (-0.10%)
DOW   33,686.54 (-0.28%)
QQQ   284.11 (+0.09%)
AAPL   143.87 (+0.86%)
MSFT   246.83 (-0.23%)
META   116.64 (+1.14%)
GOOGL   93.38 (-0.35%)
AMZN   89.47 (-0.97%)
TSLA   180.95 (+4.33%)
NVDA   173.06 (+0.80%)
NIO   12.80 (-4.55%)
BABA   91.81 (-2.51%)
AMD   69.50 (-1.38%)
T   19.20 (+0.42%)
MU   55.37 (+0.31%)
CGC   2.91 (-5.83%)
F   13.22 (+0.76%)
GE   82.21 (-1.70%)
DIS   93.94 (+1.50%)
AMC   5.85 (-3.62%)
PYPL   74.04 (-0.24%)
PFE   51.94 (+0.31%)
NFLX   324.46 (+4.58%)
NASDAQ:IDRA

Idera Pharmaceuticals - IDRA Stock Forecast, Price & News

$0.30
0.00 (-0.03%)
(As of 12/9/2022 01:20 PM ET)
Add
Compare
Today's Range
$0.29
$0.30
50-Day Range
$0.17
$0.37
52-Week Range
$0.27
$0.95
Volume
1,644 shs
Average Volume
92,569 shs
Market Capitalization
$15.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDRA stock logo

About Idera Pharmaceuticals (NASDAQ:IDRA) Stock

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Stock News Headlines

Idera Pharma Acquires Rare Disease Player, Names New CEO
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals Stock (NASDAQ:IDRA), Dividends
Why Are Idera Pharmaceuticals Shares Soaring Today
Idera Pharmaceuticals Announces Tilsotolimod Updates
IDRA Nov 2021 3.000 call
Idera Pharmaceuticals Announces Corporate Updates
See More Headlines
Receive IDRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IDRA Company Calendar

Last Earnings
11/14/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDRA
Employees
32
Year Founded
1989

Profitability

Net Income
$98.09 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.45 million
Cash Flow
$1.87 per share
Book Value
$0.56 per share

Miscellaneous

Free Float
50,371,000
Market Cap
$15.91 million
Optionable
Optionable
Beta
1.36

Social Links


Key Executives

  • Mr. John J. Kirby CPAMr. John J. Kirby CPA (Age 50)
    Chief Financial Officer
    Comp: $477.41k
  • Mr. Bryant David LimMr. Bryant David Lim (Age 51)
    Chief Bus. Officer & Gen. Counsel
    Comp: $480.96k
  • Mr. John Taylor
    CEO & Director
  • Mr. Daniel Salain (Age 55)
    Chief Operating Officer
  • Mr. Andy Jordan
    Chief Strategy Officer
  • Dr. Carl Kraus M.D.
    Chief Medical Officer
  • Dr. Shah Rahimian M.D.
    Ph.D., Medical Director & Global Clinical Lead for Oncology
  • Dr. Joanna Caroline Horobin Ch.B (Age 67)
    M.B., Advisor
  • Dr. Sudhir Agrawal D.Phil. (Age 68)
    F.R.S.C., Scientific Advisor
  • Mr. Louis J. Arcudi III (Age 61)
    M.B.A., MBA, Adviser













IDRA Stock - Frequently Asked Questions

How have IDRA shares performed in 2022?

Idera Pharmaceuticals' stock was trading at $0.2850 at the start of the year. Since then, IDRA stock has increased by 5.2% and is now trading at $0.2999.
View the best growth stocks for 2022 here
.

When is Idera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our IDRA earnings forecast
.

How were Idera Pharmaceuticals' earnings last quarter?

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) released its earnings results on Monday, November, 14th. The biotechnology company reported ($0.06) earnings per share for the quarter.

When did Idera Pharmaceuticals' stock split?

Shares of Idera Pharmaceuticals split before market open on Friday, November 25th 2022. The 2-1 split was announced on Friday, November 25th 2022. The newly created shares were distributed to shareholders after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Vincent Milano's approval rating as Idera Pharmaceuticals' CEO?

7 employees have rated Idera Pharmaceuticals Chief Executive Officer Vincent Milano on Glassdoor.com. Vincent Milano has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Idera Pharmaceuticals own?
What is Idera Pharmaceuticals' stock symbol?

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Who are Idera Pharmaceuticals' major shareholders?

Idera Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.39%), Citadel Advisors LLC (0.22%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Bryant David Lim, Daniel B Soland, Elizabeth Ann Tarka, Invest Corp Pillar, John J Kirby, John J Kirby, Jonathan Michael Yingling, Michael R Dougherty, Robert C Fletcher and Vincent Milano.
View institutional ownership trends
.

How do I buy shares of Idera Pharmaceuticals?

Shares of IDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Idera Pharmaceuticals' stock price today?

One share of IDRA stock can currently be purchased for approximately $0.30.

How much money does Idera Pharmaceuticals make?

Idera Pharmaceuticals (NASDAQ:IDRA) has a market capitalization of $15.91 million and generates $1.45 million in revenue each year. The biotechnology company earns $98.09 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How can I contact Idera Pharmaceuticals?

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The official website for the company is www.iderapharma.com. The biotechnology company can be reached via phone at (484) 348-1600, via email at jconwell@iderapharma.com, or via fax at 617-679-5592.

This page (NASDAQ:IDRA) was last updated on 12/9/2022 by MarketBeat.com Staff